However, since it is efficient (in combination) in patients with tumors overexpressing CCND1 such as mantle cell lymphoma or HR+ breast cancer, it might be of interest for patients with t(11;14) without Rb deficiency [46, 47]. This evidence concerns the gene RB1 and breast cancer.